• Japanese
  • Korean
  • Chinese
Cover Image

PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013

Abstract

PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013

Summary

"PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013" applies GlobalData's proprietary ranking methodology to compare the competitive position of 30 generic pharmaceutical companies across various markets on 12 financial metrics. The performances of these companies are analyzed based on financial performance, cost-containment, capital structure, and efficiency to illustrate the different strategies these companies are using to increase shareholder value and capture market share from branded pharmaceuticals manufacturers. In addition to the financial metrics, this report presents SWOT analyses of the major players, and describes the operations strategy of these companies.

Throughout the report, GlobalData's analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions.

Scope

  • The report provides analysis of the key drivers and trends shaping the global generics industry.
  • The report identifies the key generic players in various markets, including a special focus on emerging markets such as India, China, Russia, and Brazil.
  • Furthermore, it provides detailed analysis of the various generic markets including the US, Europe, APAC, and BRIC.
  • The report contains expert insights on the corporate strategies of generic companies seeking competitive advantage in the highly competitive generics industry.

Reasons to buy

  • Benchmark your company's performance against other generic pharmaceutical companies to identify strengths that can be leveraged and/or areas of possible improvement
  • Analyze and track the strategies that successful generic pharmaceutical companies are using to gain share in the increasingly competitive market
  • Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending, asset structure, and efficiency
  • Use this information as an independent source for your due diligence and transaction strategy

TOC

1 Table of Contents

1 Table of Contents 6

  • 1.1 List of Tables 10
  • 1.2 List of Figures 11

2 Introduction 13

  • 2.1 Report Scope 13
  • 2.2 Upcoming Related Reports 15
  • 2.3 Recently Published Reports 15
  • 2.4 GlobalData's Benchmarking Methodology 16

3 GlobalData Benchmark Rankings 17

  • 3.1 Sun Pharmaceuticals Emerges as Generics Leader 17

4 Financial Management 19

  • 4.1 Competitive Framework 19
  • 4.2 Overview 19
  • 4.3 Financial Management: Heat Map 22
  • 4.4 Financial Metrics 24
    • 4.4.1 Revenue Leaders 24
    • 4.4.2 Revenue Laggards 26
    • 4.4.3 Revenue Growth Leaders 28
    • 4.4.4 Revenue Growth Laggards 30
    • 4.4.5 Operating Income Leaders 32
    • 4.4.6 Operating Income Laggards 33
    • 4.4.7 Operating Income YTY Growth Leaders 35
    • 4.4.8 Operating Income YTY Growth Laggards 36
    • 4.4.9 Operating Margin Leaders 39
    • 4.4.10 Operating Margin Laggards 40

5 Expense Management 43

  • 5.1 Competitive Framework 43
  • 5.2 Overview 43
  • 5.3 Expense Management: Heat Map 46
  • 5.4 Expense Metrics 48
    • 5.4.1 SG&A Spending Leaders 48
    • 5.4.2 SG&A Spending Laggards 49
    • 5.4.3 SG&A YTY Change Leaders 51
    • 5.4.4 SG&A YTY Change Laggards 52
    • 5.4.5 Operating Expense Leaders 54
    • 5.4.6 Operating Expense Laggards 55

6 Capital Management 58

  • 6.1 Competitive Framework 58
  • 6.2 Overview 58
  • 6.3 Competitive Framework: Heat Map 60
  • 6.4 Capital Management Metrics 61
    • 6.4.1 Debt-to-Assets Leaders 61
    • 6.4.2 Debt-to-Assets Laggards 63
    • 6.4.3 Cash Ratio Leaders 65
    • 6.4.4 Cash Ratio Laggards 67
    • 6.4.5 ROI Leaders 69
    • 6.4.6 ROI Laggards 70

7 Key Players 72

  • 7.1 Strategic Analysis of Leading Generics Players 72
    • 7.1.1 Sun Pharmaceuticals: The Benchmark Leader 72
    • 7.1.2 Sandoz 76
    • 7.1.3 Pharmstandard 79
    • 7.1.4 Teva Pharmaceuticals 81
    • 7.1.5 Actavis 86
    • 7.1.6 Mylan 90
    • 7.1.7 Ranbaxy 93
    • 7.1.8 Dr. Reddy's 94
    • 7.1.9 Covidien 95
    • 7.1.10 Hospira 96

8 Outlook 97

  • 8.1 Leverage Improvement will Significantly Alter 2013 Benchmark Rankings 97
  • 8.2 Generic Manufacturers in Emerging Markets will continue to Challenge for Top Spots 97

9 Appendix 99

  • 9.1 Bibliography 99
  • 9.2 Abbreviations 99
  • 9.3 Research Methodology 101
    • 9.3.1 Coverage 101
    • 9.3.2 Secondary Research 102
    • 9.3.3 Expert Panel Validation 102
  • 9.4 About the Authors 102
    • 9.4.1 Analyst 102
    • 9.4.2 Director of Healthcare Industry Dynamics 103
    • 9.4.3 Global Head of Healthcare Research and Consulting 103
  • 9.5 About the Industry Dynamics Team 104
  • 9.6 About GlobalData 104
  • 9.7 Contact Us 104
  • 9.8 Disclosure Information 105
  • 9.9 Disclaimer 105

List of Tables

1.1 List of Tables

  • Table 1: GlobalData Benchmark Rankings, FY2012 18
  • Table 2: Top 15 Companies FM Composite Scores and Overall FM Score, 2012 22
  • Table 3: Bottom 15 Companies' FM Composite Scores and Overall FM Score, 2012 23
  • Table 4: FY2012 Top Three Revenue Leaders 24
  • Table 5: FY2012 Top Three Revenue Laggards 26
  • Table 6: FY2012 Top Three Revenue Growth Leaders 28
  • Table 7: FY2012 Top Three Revenue Growth Laggards 30
  • Table 8: FY2012 Top Three Operating Income Leaders 32
  • Table 9: FY2012 Top Three Operating Income Laggards 33
  • Table 10: FY2012 Top Three YTY Operating Income Growth Leaders 35
  • Table 11: FY2012 Top Three YTY Operating Income Growth Laggards 36
  • Table 12: FY2012 Top Three Operating Margin Leaders 39
  • Table 13: FY2012 Top Three Operating Margin Laggards 40
  • Table 14: Top 15 Companies' EM Composite Scores and Overall EM Score, 2012 46
  • Table 15: Bottom 15 Companies' EM Composite Scores and Overall EM Score, 2012 47
  • Table 16: FY2012 Top SG&A Spending Leaders as a Percentage of Revenue 48
  • Table 17: FY2012 Top R&D Spending Laggards as a Percentage of Revenue 49
  • Table 18: FY2012 Top SG&A YTY Change Leaders 51
  • Table 19: FY2012 Top SG&A YTY Change Laggards 52
  • Table 20: FY2012 Top Operating Expense Leaders as a Percentage of Revenue 54
  • Table 21: FY2012 Top Operating Expense Laggards as a Percentage of Revenue 55
  • Table 22: Top 15 Companies' CM Composite Scores and Overall CM Score, 2012 60
  • Table 23: Bottom 15 Companies' CM Composite Scores and Overall CM Score, 2012 61
  • Table 24: FY2012 Top Debt-to-Assets Leaders 61
  • Table 25: FY2012 Debt-to-Assets Laggards 63
  • Table 26: FY2012 Cash Ratio Leaders 65
  • Table 27: FY2012 Cash Ratio Laggards 67
  • Table 28: FY2012 ROI Leaders 69
  • Table 29: FY2012 ROI Laggards 70

List of Figures

1.2 List of Figures

  • Figure 1: Generics Manufacturing Landscape Assessment - FY2012 Corporate Revenue Growth vs. Operating Margin 20
  • Figure 2: Generics Manufacturing Landscape Assessment - FY2012 Generics Sales Growth vs. Operating Margin 21
  • Figure 3: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Revenue 27
  • Figure 4: FY2012 Leading Generic Pharmaceutical Companies by YTY Revenue Growth 31
  • Figure 5: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Income ($m) 35
  • Figure 6: FY2012 Leading Generic Pharmaceutical Companies by YTY Operating Income Growth 38
  • Figure 7: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Margin 42
  • Figure 8: Top 30 Generic Pharmaceutical Landscape Assessment - FY2012 SG&A Expense vs. Operating Expense as a Percentage of Revenue 44
  • Figure 9: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending ($m) 45
  • Figure 10: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending as a Percentage of Revenue 50
  • Figure 11: FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending as a Percentage of Revenue, YTY Change 53
  • Figure 12: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Expense as a Percentage of Revenue 57
  • Figure 13: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Debt-to-Assets Ratio 65
  • Figure 14: FY 2011 and FY2012, Leading Generic Pharmaceutical Companies by Cash Ratio 68
  • Figure 15: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by ROI 71

Figure 16: Sun Pharmaceuticals: SWOT Analysis 73

Figure 17: Sandoz: SWOT Analysis 76

Figure 18: Pharmstandard: SWOT Analysis 79

Figure 19: Teva Pharmaceuticals: SWOT Analysis 82

  • Figure 20: Teva Generics Sales in US vs. Rest-of-World (ROW)1, 2009-2012 85

Figure 21: Actavis: SWOT Analysis 87

Figure 22: Mylan: SWOT Analysis 90

Figure 23: Ranbaxy: SWOT Analysis 93

Figure 24: Dr. Reddy's: SWOT Analysis 94

Figure 25: Covidien: SWOT Analysis 95

Figure 26: Hospira: SWOT Analysis 96

Show More
Pricing
Get Notified
Email me when related reports are published